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Abstract Protein kinase C (PKC) activation induces neuronal
differentiation of SH-SY5Y neuroblastoma cells. This study
examines the role of PKCL isoforms in this process. The PKCL-
specific inhibitor LY379196 had no effect on 12-O-tetradeca-
noylphorbol 13-acetate (TPA)-induced neurite outgrowth from
SH-SY5Y neuroblastoma cells. On the other hand, PKCL
inhibition suppressed the TPA-stimulated increase in neuropep-
tide Y mRNA, activation of neuropeptide Y gene promoter
elements, and phosphorylation of Erk1/2. The TPA-induced
increase in neuropeptide Y expression was also inhibited by the
MEK inhibitor PD98059. These data indicate that activation of
a PKCL isoform, through a pathway involving Erk1/2, leads to
increased expression of neuronal differentiation genes in
neuroblastoma cells. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Neuroblastoma cells are derived from the sympathetic nerv-
ous system and phenotypically resemble immature sympa-
thetic neuroblasts [1]. It has been suggested that neuroblasto-
ma cells have been arrested at an immature di¡erentiation
state and one way to halt the malignancy of these cells would
be to induce them to di¡erentiate towards mature sympathetic
neurons.
Several neuroblastoma di¡erentiation protocols have been
characterized in vitro, for instance treatment with retinoic
acid [2]. In the SH-SY5Y neuroblastoma cell line treatment
with phorbol esters, at concentrations that activate but do not
down-regulate protein kinase C (PKC), leads to sympathetic
neuronal di¡erentiation with neurite outgrowth and increased
synthesis of noradrenaline and expression of neuropeptide Y
(NPY) and growth-associated protein 43 (GAP-43). These
e¡ects are mediated by and dependent on PKC [3^6].
PKC constitutes a family of related serine/threonine ki-
nases. Based on structural and regulatory properties this fam-
ily can be divided into classical (PKCK, LI, LII, and Q), novel
(PKCN, O, R, and a), and atypical (PKCS/V and j) isoforms.
We have previously demonstrated that a classical isoform,
most likely PKCLI, has a stimulatory e¡ect on neuroblastoma
cell proliferation [7]. We have also shown that the novel iso-
form PKCO can elicit morphological changes, such as neurite
outgrowth, associated with neuronal di¡erentiation [8]. How-
ever, during 12-O-tetradecanoylphorbol 13-acetate (TPA)-in-
duced di¡erentiation of neuroblastoma cells it is likely that a
classical isoform is involved in the induction of di¡erentiation
marker genes [9]. The aim of this study was to elucidate
whether the PKCL isoforms are implicated in the TPA-in-
duced neuronal di¡erentiation of SH-SY5Y neuroblastoma
cells.
2. Materials and methods
2.1. Cell culture
SH-SY5Y cells, kindly provided by Dr. J. Biedler, Memorial Sloan-
Kettering Cancer Center, New York, NY, USA, were maintained in
Eagle’s minimal essential medium supplemented with 10% fetal calf
serum, 100 IU/ml penicillin and 100 Wg/ml streptomycin (Gibco).
2.2. Morphology studies
Cells were seeded in regular growth medium at a density of 150 000
cells per 60 mm dish. When indicated, medium was supplemented with
16 nM TPA (Sigma) or LY379196 (kindly provided by Eli Lilly Re-
search Laboratories). This compound was shown to have in vitro IC50
values of 50 nM for PKCLI, 30 nM for PKCLII, and 600 nM or
above for other PKC isoforms present in neuroblastoma cells (as
communicated by Eli Lilly Research Laboratories). After 4 days phase
contrast images were captured with a Sony DKC 5000 camera system.
2.3. Northern blot analysis
4U106 SH-SY5Y cells were seeded in 100 mm dishes and 24 h later
TPA and kinase inhibitors were added. After an additional incubation
for 24 h total RNA was extracted using Trizol (Gibco) essentially
according to the manufacturer’s instructions. 15 Wg RNA was sepa-
rated on a denaturing agarose gel and thereafter transferred to Hy-
bond N membrane (Amersham) by Northern blotting as described
[10]. Hybridization was done with [32P]dCTP-labeled NPY, GAP-43
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
probes.
2.4. Luciferase assay
A plasmid, kindly provided by Dr. Carolyn Minth-Worby [11],
containing the NPY gene promoter element 387 to 347 fused to
the minimal herpes simplex virus thymidine kinase promoter, was
used as template for a PCR reaction. In this reaction primers con-
taining HindIII and SalI sites were used to amplify a fragment en-
compassing the NPY promoter elements and the minimal thymidine
kinase promoter. The fragment was initially inserted into the pEGFP-
1 vector (Clontech) and thereafter a SmaI/SacI fragment was trans-
ferred to the pGL3Basic vector (Promega) which contains cDNA for
luciferase as reporter thereby generating the NPY(387/347)TKLuc
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vector. The resulting PCR product was sequenced to exclude the
possibility of base changes in the PCR reactions.
For promoter activity analysis, SH-SY5Y cells were seeded at a
density of 1U106 per 60 mm dish. Cells were transfected 24 h later
with the NPY(387/347)TKLuc vector using Lipofectamine (Gibco)
according to the supplier’s protocol. After transfection cells were in-
cubated for 16 h in serum-free medium with TPA, and GF109203X,
Go«6976, Go«6983, PD98059 (all Calbiochem) or LY379196. Luciferase
activity was measured with a Luciferase Assay System (Promega) ac-
cording to the supplier’s protocol. The coe⁄cient of analytical varia-
tion for this assay was determined to be 0.042.
2.5. Analysis of Erk1/2 phosphorylation
Following stimulation cells were put on ice and washed with ice-
cold phosphate-bu¡ered saline and harvested in lysis bu¡er (25 mM
Tris^HCl, pH 7.5, 1% Triton X-100, 150 mM NaCl, 1 mM dithio-
threitol, 1 mM ethylenediaminetetraacetic acid and Complete Protease
Inhibitor cocktail [Roche]). Lysates were centrifuged for 10 min at
15 000 rpm and 25 Wg proteins from the supernatants were separated
on a 10% polyacrylamide gel and transferred to Hybond-C extra
nitrocellulose ¢lter (Amersham Pharmacia Biotech). Filters were ana-
lyzed with primary antibodies towards phosphorylated (New England
Biolabs) and total (Transduction Laboratories) Erk1/2 followed by
secondary horseradish peroxidase-labeled antibodies. Immunoreactiv-
ity was visualized with Super Signal (Pierce) and chemiluminescence
was captured with a CCD camera (Fuji¢lm).
3. Results
To explore whether PKCL isoforms are involved in TPA-
induced morphological di¡erentiation of SH-SY5Y cells, the
cells were treated with 16 nM TPA for 4 days in the absence
or presence of the speci¢c PKCL inhibitor LY379196 (Fig. 1).
This TPA treatment leads to neuronal di¡erentiation of SH-
SY5Y which can be blocked by PKC inhibitors [3,6]. Inclu-
sion of TPA in the medium elicited a morphological di¡er-
entiation of the cells with neurites bearing varicosities. Con-
comitant incubation with 100 or 300 nM LY379196 did not
in£uence this morphological e¡ect and thus implies that the
activity of PKCL isoforms is not crucial for the induction of
morphological features of neuronal di¡erentiation.
Another feature of TPA-di¡erentiated SH-SY5Y cells is the
increased expression of sympathetic neuronal marker genes
such as NPY and GAP-43. This TPA e¡ect is completely
blocked by PKC inhibitors [9]. To investigate whether a
PKCL isoform mediates this e¡ect, we analyzed the expression
of NPY and GAP-43 upon treatment with 16 nM TPA in the
absence or presence of 100 nM LY379196 (Fig. 2). This ex-
periment revealed that 100 nM LY379196, a concentration
that is two to three times the reported in vitro IC50 value
for PKCL but less than one ¢fth of the corresponding value
for other isoforms present in neuroblastoma cells, abolished
TPA-induced NPY expression in the absence of serum and
markedly suppressed it in the presence of serum. Since PKC
activation frequently leads to activation of the mitogen-acti-
vated protein kinases Erk1/2 and since activation of these ki-
nases is associated with neuronal di¡erentiation, we also in-
vestigated the e¡ect of the MEK inhibitor PD98059, which
will block the activation of Erk1/2 (Fig. 2). This compound
also suppressed the TPA-stimulated increase in NPY mRNA
indicating that Erk1/2 is involved in this e¡ect. The pattern
was similar for the TPA-stimulated increase in GAP-43
mRNA levels. In the absence of serum, LY379196 blocked
the TPA e¡ect and in the presence of serum it was suppressed.
PD98059 inhibited the increase in GAP-43 mRNA both in the
absence and in the presence of serum.
A part of the sequence upstream of the transcription start
in the NPY gene has been identi¢ed to be responsive to stim-
uli that lead to increased NPY expression [11]. Using reporter
genes the sequence has been shown to drive transcription
upon stimulation with several factors, including TPA, that
elicit neuronal di¡erentiation in SH-SY5Y cells [12,13]. We
subcloned this promoter sequence in the pGL3Basic vector
which contains luciferase cDNA as the reporter gene. SH-
SY5Y cells were transfected with the vector and thereafter
treated with TPA and increasing concentrations of two PKC
inhibitors, Go«6976 which only inhibits classical PKC isoforms
and the PKCL-speci¢c inhibitor LY379196 (Fig. 3A). Both
inhibitors attenuated the TPA-stimulated luciferase expression
at concentrations which are compatible with a mechanism
Fig. 1. Inhibition of PKCL isoforms does not lead to suppression of TPA-induced neurite outgrowth. Phase contrast images of SH-SY5Y cells
grown for 4 days in serum-containing medium in the absence (A^C) or presence (D^F) of 16 nM TPA together with vehicle only (A and D),
100 nM (B and E) or 300 nM (C and F) of the PKCL inhibitor LY379196.
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involving a PKCL isoform. This TPA e¡ect was also blocked
by the pan-PKC inhibitors Go«6983 and GF109203X and by
suppression of the Erk1/2 pathway by PD98059 (Fig. 3B).
Since inhibition of either Erk1/2 or PKCL isoforms sup-
presses TPA-stimulated NPY expression and promoter activ-
ity we investigated whether TPA treatment would induce
phosphorylation of Erk1/2 through a pathway that is depen-
dent on PKCL activity. SH-SY5Y cells were treated with TPA
and the phosphorylation of Erk1/2 was analyzed (Fig. 4).
Initially a time course study for the TPA e¡ect was performed
and this demonstrated that there is a rapid phosphorylation of
Erk, detectable already after 3 and peaking after 10 min of
TPA treatment (Fig. 4A). We thereafter examined the e¡ect of
PKC inhibitors and the MEK inhibitor PD98059 on TPA-
stimulated phosphorylation of Erk (Fig. 4B,C). These experi-
ments showed that blocking MEK activity with PD98059 or
inhibiting all PKC isoforms using GF109203X and Go«6983
abolished TPA-stimulated Erk1/2 phosphorylation both in the
absence and in the presence of serum. The PKCL inhibitor
LY379196 at 100 nM markedly suppressed the same e¡ect
indicating that a PKCL isoform at least partially mediates
the TPA-induced activation of Erk1/2.
4. Discussion
There are several reports demonstrating a role for di¡erent
PKC isoforms in the induction of neuronal di¡erentiation.
Primarily the novel isoforms PKCN and O have been suggested
to be involved in this process [6,14^18]. In neuroblastoma
cells, PKCO has been shown to induce neurite outgrowth with-
out an accompanying increase in the expression of neuronal
di¡erentiation marker genes [8]. This study demonstrates that
a PKCL isoform can mediate the induction of the neuronal
marker genes NPY and GAP-43. Hence di¡erent PKC iso-
forms seem to mediate di¡erent aspects of the neuronal di¡er-
entiation process which indicates that it is necessary to acti-
vate several isoforms to obtain a complete di¡erentiation.
The PKCL inhibitor did not completely abolish the TPA-
stimulated increase in NPY and GAP-43 mRNA. This could
be due to the concentration of the inhibitor, 100 nM, which is
only two to three times the reported IC50 for inhibition of
PKCLI and LII in vitro. We refrained from using higher con-
centrations in most experiments since under such conditions
other PKC isoforms may also be inhibited. Thus the lack of
complete suppression may be caused by a fraction of the
PKCL activity that is not inhibited by 100 nM LY379196.
In the reporter assay, where higher concentrations were
used, the TPA-stimulated NPY promoter activity was indeed
abolished by LY379196 which indicates that a complete sup-
pression of PKCL activity abolishes the TPA e¡ect on NPY
expression. However, it cannot be excluded that at the higher
LY379196 concentrations other PKC isoforms are also af-
fected which could potentially explain the complete suppres-
sion by the higher concentrations. This would imply that there
Fig. 2. TPA-stimulated increase in NPY and GAP-43 expression is
suppressed by inhibitors of PKCL and MEK. SH-SY5Y cells were
grown for 24 h in the absence (A) or presence (B) of serum and
treated with 16 nM TPA in the absence or presence of 100 nM
LY379196 (LY) or PD98059 (PD). Total RNA was thereafter ex-
tracted and the expression of NPY, GAP-43 and GAPDH was ana-
lyzed by Northern blot. The blots are representative of three sepa-
rate experiments.
Fig. 3. TPA-stimulated activation of the NPY promoter is attenuated by PKC and MEK inhibitors. SH-SY5Y cells were transfected with the
vector encoding the luciferase reporter gene under the control of the NPY promoter element 387 to 347 and the minimal thymidine kinase
promoter. Cells were grown for 16 h in serum-free medium with or without 16 nM TPA and treated with (A) increasing concentrations of the
PKCL inhibitor LY379196 or the cPKC inhibitor Go«6976, or (B) either the PKCL inhibitor LY379196 (100 nM), two general PKC inhibitors
GF109203X (2 WM) and Go«6983 (2 WM), or the MEK inhibitor PD98059 (50 WM). Luciferase activity was thereafter assayed and the data are
shown as relative values where the activity for TPA-stimulated cells is 100%.
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is a redundancy in the system, particularly evident in the
presence of serum, with several PKC isoforms mediating the
e¡ects on gene expression. We have previously seen that TPA-
stimulated NPY expression can be completely abrogated by
the inhibitor of classical PKC isoforms Go«6976 [9]. It is thus
likely that this alternative PKC isoform is PKCK, since PKCQ
is not expressed in these cells.
Activation of Erk1/2 has frequently been connected to in-
duction of a di¡erentiation process and it is activated during
neuronal di¡erentiation of neuroblastoma cells [19]. Accord-
ingly, inhibition of Erk1/2 activation suppressed TPA-stimu-
lated NPY and GAP-43 expression. Furthermore, pan-PKC
inhibitors abolished TPA-stimulated phosphorylation of Erk1/
2 clearly highlighting Erk1/2 as a mediator of PKC-induced
increase in the expression of neuronal marker genes. A crucial
role for Erk1/2 in the TPA-mediated increase in NPY and
GAP-43 expression has also recently been demonstrated
[20]. In that study it was also shown that suppression of
Erk1/2 did not in£uence the morphological di¡erentiation in-
duced by TPA. Together with the data in this study this
clearly illustrates that a PKCL-Erk1/2 pathway is involved
in the up-regulation of di¡erentiation genes but not in the
morphological changes during di¡erentiation of neuroblasto-
ma cells.
In several cell systems activation of PKC leads to stimula-
tion of the Erk1/2 pathway. PKCK [21], L [22], N [18], O [21], as
well as j [23] have been shown to activate the Erk pathway in
di¡erent cell types. Furthermore, it seems likely that most, if
not all, PKC isoforms have the capacity to induce activation
of Erk1/2 when overexpressed in the same cell [24,25]. These
¢ndings may indicate that there is either a redundancy so that
several isoforms can mediate the same e¡ect or that for each
cell there are conditions which determine which isoform can
transduce the signal. This could be caused by the expression
pattern of PKC isoforms in the particular cell or by cell-spe-
ci¢c expression of interacting proteins which direct particular
isoforms to the site of action in the transduction cascade. It
illustrates the necessity to identify the PKC isoform involved
in each individual case of PKC-mediated Erk1/2 activation.
Our data clearly show that a PKCL isoform is involved in
phorbol ester-stimulated activation of Erk1/2 in the SH-
SY5Y neuroblastoma cells. However, the PKCL inhibitor
did not completely abolish the phosphorylation of Erk1/2 as
the pan-PKC inhibitors did. This could be due to either a
redundancy or incomplete suppression by LY379196 as dis-
cussed above for the induction of NPY expression.
In conclusion, this study demonstrates that activation of
PKCL can induce the expression of neuronal di¡erentiation
genes in neuroblastoma cells through activation of the Erk1/2
pathway. The PKC-stimulated morphological di¡erentiation,
on the other hand, is not dependent on PKCL illustrating that
di¡erent PKC isoforms elicit di¡erent features of the neuronal
di¡erentiation program.
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